Investigating hearing loss caused by aminoglycoside antibiotics in infants
Clinical factors in aminoglycoside-induced ototoxicity
This study is looking at how higher doses of a common antibiotic called gentamicin, used to treat infections in newborns, might affect their hearing, especially for babies in intensive care, so we can find ways to prevent any hearing loss while still helping them get better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Creighton University NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project ID | NIH-10653034 on NIH RePORTER |
What this research studies
This research focuses on understanding how aminoglycoside antibiotics, commonly used to treat bacterial infections in infants, may lead to hearing loss. The study aims to determine if higher doses of gentamicin, a type of aminoglycoside, are linked to increased hearing impairment in newborns, particularly those in neonatal intensive care units (NICUs). By examining the relationship between antibiotic dosage and hearing outcomes, the researchers hope to identify risk factors that could help prevent drug-induced hearing loss. The ultimate goal is to improve the quality of life for infants who are treated with these life-saving medications.
Who could benefit from this research
Good fit: Ideal candidates for this research are infants receiving aminoglycoside antibiotics in NICUs, particularly those with suspected sepsis.
Not a fit: Patients who are not receiving aminoglycoside antibiotics or who are not in the neonatal intensive care unit may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to strategies that minimize the risk of hearing loss in infants treated with aminoglycosides.
How similar studies have performed: While there have been pilot studies indicating a risk of hearing loss associated with aminoglycosides, this research aims to provide more rigorous data on the topic.
Where this research is happening
Omaha, United States
- Creighton University — Omaha, United States (Active)
Researchers
- Principal investigator: Steyger, Peter Stephen — Creighton University
- Study coordinator: Steyger, Peter Stephen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.